Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 2,913.7	$ 1,224.6
Marketable securities	1,562.2	2,313.4
Accounts receivable, net	1,880.5	1,958.5
Due from anti-CD20 therapeutic programs	590.2	526.9
Inventory	804.2	929.9
Other current assets	631.0	687.6
Total current assets	8,381.8	7,640.9
Marketable securities	1,408.1	1,375.9
Property, plant and equipment, net	3,247.3	3,601.2
Operating lease assets	427.0	0.0
Intangible assets, net	3,527.4	3,120.0
Goodwill	5,757.8	5,706.4
Deferred tax asset	3,232.1	2,153.9
Investments and other assets	1,252.8	1,690.6
Total assets	27,234.3	25,288.9
Current liabilities:
Current portion of notes payable	1,495.8	0.0
Taxes payable	71.4	63.5
Accounts payable	530.8	370.5
Accrued expenses and other	2,765.8	2,861.2
Total current liabilities	4,863.8	3,295.2
Notes payable	4,459.0	5,936.5
Deferred tax liability	2,810.8	1,636.2
Operating lease liability, noncurrent	412.7	0.0
Other long-term liabilities	1,348.9	1,389.4
Total liabilities	13,895.2	12,257.3
Commitments and contingencies
Biogen Idec Inc. shareholders' equity
Preferred stock, par value $0.001 per share	0.0	0.0
Common stock, par value $0.0005 per share	0.1	0.1
Additional paid-in capital	0.0	0.0
Accumulated other comprehensive loss	(135.2)	(240.4)
Retained earnings	16,455.4	16,257.0
Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively	(2,977.1)	(2,977.1)
Total Biogen Inc. shareholders’ equity	13,343.2	13,039.6
Noncontrolling interests	(4.1)	(8.0)
Total equity	13,339.1	13,031.6
Total liabilities and equity	$ 27,234.3	$ 25,288.9